Skip to content
← All settings

DISEASE & TREATMENT SETTING

Primary Systemic Amyloidosis

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Primary Systemic Amyloidosis

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 8 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      8 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00112593 · Registry condition search · Scope: narrower

      Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00520767 · Registry condition search · Scope: narrower

      Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00536601 · Registry condition search · Scope: narrower

      High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

      4 outcome links · 5 safety-group records · 0 quality-of-life measures

      →

      NCT01072773 · Registry condition search · Scope: narrower

      Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT01078454 · Registry condition search · Scope: narrower

      Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

      1 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT01849783 · Registry condition search · Scope: narrower

      Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

      4 outcome links · 7 safety-group records · 1 quality-of-life measures

      →

      NCT02207556 · Registry condition search · Scope: narrower

      Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial

      5 outcome links · 2 safety-group records · 2 quality-of-life measures

      →

      NCT03499808 · Registry condition search · Scope: narrower

      S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-primary-systemic-amyloidosis
        binding id
        ncit-C8299
        source collection
        ncit-concept
        source key
        C8299
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice